These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 358897)

  • 21. [Pompe's disease].
    Laforêt P
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S290-1. PubMed ID: 18029059
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA approves new treatment for late-onset Pompe disease.
    Home Healthc Nurse; 2010 Sep; 28(8):457. PubMed ID: 20811179
    [No Abstract]   [Full Text] [Related]  

  • 23. An appraisal of human trials in enzyme replacement therapy of genetic diseases.
    Tager JM; Hamers MN; Schram AW; Van den Bergh FA; Rietra PJ; Loonen C; Koster JF; Slee R
    Birth Defects Orig Artic Ser; 1980; 16(1):343-59. PubMed ID: 6778527
    [No Abstract]   [Full Text] [Related]  

  • 24. Glycogen storage disease types I and II: treatment updates.
    Koeberl DD; Kishnani PS; Chen YT
    J Inherit Metab Dis; 2007 Apr; 30(2):159-64. PubMed ID: 17308886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Penetration of target areas in the rat by liposome-associated agents administered parenterally and intragastrically.
    Gregoriadis G; Dapergolas G; Neerunjun ED
    Biochem Soc Trans; 1976; 4(2):256-9. PubMed ID: 63398
    [No Abstract]   [Full Text] [Related]  

  • 26. alpha-glucosidase (CHO) (Genzyme).
    Lachmann RH
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1101-10. PubMed ID: 15535432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach.
    Ing RJ; Cook DR; Bengur RA; Williams EA; Eck J; Dear Gde L; Ross AK; Kern FH; Kishnani PS
    Paediatr Anaesth; 2004 Jun; 14(6):514-9. PubMed ID: 15153218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA, liposomes, and proteins as carriers for antitumoral drugs.
    Trouet A; Baurain R; Deprez-De Campeneere D; Layton D; Masquelier M
    Recent Results Cancer Res; 1980; 75():229-35. PubMed ID: 7232835
    [No Abstract]   [Full Text] [Related]  

  • 29. Liposomes as drug carriers in cancer chemotherapy.
    Weinstein JN; Leserman LD
    Pharmacol Ther; 1984; 24(2):207-33. PubMed ID: 6379684
    [No Abstract]   [Full Text] [Related]  

  • 30. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
    Su J; Sherman A; Doerfler PA; Byrne BJ; Herzog RW; Daniell H
    Plant Biotechnol J; 2015 Oct; 13(8):1023-32. PubMed ID: 26053072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
    Winkel LP; Kamphoven JH; van den Hout HJ; Severijnen LA; van Doorn PA; Reuser AJ; van der Ploeg AT
    Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical observation on human alpha glucosidase in treatment of five patients with glycogen storage disease Ⅱ].
    Xu LL; Zhang LD; Liang YJ; Tang W; Huang XQ; Pei YX; Cheng YC; Huang HM; Zhang C
    Zhonghua Er Ke Za Zhi; 2016 Nov; 54(11):829-833. PubMed ID: 27806790
    [No Abstract]   [Full Text] [Related]  

  • 33. Radionuclide-labelled liposomes--a new lymph node imaging agent.
    Osborne MP; Richardson VJ; Jeyasingh K; Ryman BE
    Int J Nucl Med Biol; 1979; 6(2):75-83. PubMed ID: 113357
    [No Abstract]   [Full Text] [Related]  

  • 34. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
    But WM; Lee SH; Chan AO; Lau GT
    Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phospholipid composition of small unilamellar liposomes containing melphalan influences drug action in mice bearing PC6 tumours.
    Large P; Gregoriadis G
    Biochem Pharmacol; 1983 Apr; 32(7):1315-8. PubMed ID: 6847720
    [No Abstract]   [Full Text] [Related]  

  • 36. Sudden deterioration in nonclassical infantile-onset Pompe disease responding to alglucosidase alfa infusion therapy: a case report.
    Pascual-Pascual SI; Rubio P; Albajara L; Gutierrez M; Chabas A; Alvarado F
    J Inherit Metab Dis; 2006 Dec; 29(6):763. PubMed ID: 17041744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carrier activity of sonicated small liposomes containing melphalan to regional lymph nodes of rats.
    Khato J; del Campo AA; Sieber SM
    Pharmacology; 1983; 26(4):230-40. PubMed ID: 6844398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II.
    Ravaglia S; Danesino C; Pichiecchio A; Repetto A; Poloni GU; Rossi M; Fratino P; Moglia A; Costa A
    Adv Ther; 2008 Aug; 25(8):820-9. PubMed ID: 18704279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzyme therapy for Pompe disease: from science to industrial enterprise.
    Reuser AJ; Van Den Hout H; Bijvoet AG; Kroos MA; Verbeet MP; Van Der Ploeg AT
    Eur J Pediatr; 2002 Oct; 161 Suppl 1():S106-11. PubMed ID: 12373583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rat heart perfusion as model system for enzyme replacement therapy in glycogenosis type II.
    van der Ploeg AT; van der Kraaij AM; Willemsen R; Kroos MA; Loonen MC; Koster JF; Reuser AJ
    Pediatr Res; 1990 Oct; 28(4):344-7. PubMed ID: 2235132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.